JPI HEALTHCARE SOLUTIONS ANNOUNCES NEW RELATIONSHIP WITH CARESTREAM HEALTH

Published on:

Plainview, NY – February 2017 — JPI Healthcare announces that we are now representing the Carestream Health product line. JPI is pleased to be able to provide a greater range of Digital Solutions to our growing dealer network. JPI Healthcare will represent the Carestream Vita Flex and Image Suite Software portfolio in the U.S.A., Canada, and Latin America. Carestream Health will benefit from the International network footprint of JPI Healthcare dealer partners. In addition, JPI Healthcare will represent the DryView Laser Imager portfolio in the U.S.A.

JPI Dealers will greatly benefit from this new business relationship. JPI is extremely proud to be able to offer its dealer’s access to Carestream Health Digital Solutions. These world-class products will undoubtedly open up new markets and new sales opportunities for both companies.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.